Clinical trial · Observational
Diagnostic Performance of 18F-FDG PET/CT in Detecting Distant Metastases in Breast Cancer
Diagnostic Performance of F18-FDG PET/CT in Detecting Distant Metastases in Breast Cancer
NCT07523516CI-TRIAL-00107924not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
compare the accuracy and sensitivity of 18F FDG-PET/CT and CE-CT in detecting distant metastases in breast cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer (Locally Advanced or Metastatic) | Malignant Breast Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Breast cancer Patients
- description
- 18 FDG PET CT scan for metastatic breast cancer
Primary outcomes (1)
- measure
- Comparison between 18F-FDG PET/CT and CT in detecting distant metastases.
- timeFrame
- 12 months
- description
- Comparison between 18F-FDG PET/CT and CT in detecting distant metastases.
Secondary outcomes (1)
- measure
- Early staging and clinical management of breast cancer in attempt to improve survival and quality of life
- timeFrame
- 12 months
- description
- Early staging and clinical management of breast cancer in attempt to improve survival and quality of life
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
1. Inclusion criteria: 1. Patients with pathologically proven breast cancer 2. Metastatic breast cancer proved by pathology or radiological modalities. 3. Interval between 18F-FDG PET/CT and CE-CT from one to three weeks. 2. Exclusion criteria: 1. Patients with known concomitant malignancy 2. Patients receive systemic treatment chemotherapy or radiotherapy between 18F-FDG PET/CT and CE-CT.
References
Publications (9)
- BACKGROUNDNiikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist. 2011;16(8):1111-9. doi: 10.1634/theoncologist.2011-0089. Epub 2011 Jul 17. PMID 21765193
- BACKGROUNDPaydary K, Seraj SM, Zadeh MZ, Emamzadehfard S, Shamchi SP, Gholami S, Werner TJ, Alavi A. The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. Mol Imaging Biol. 2019 Feb;21(1):1-10. doi: 10.1007/s11307-018-1181-3. PMID 29516387
- BACKGROUNDVercher-Conejero JL, Pelegri-Martinez L, Lopez-Aznar D, Cozar-Santiago Mdel P. Positron Emission Tomography in Breast Cancer. Diagnostics (Basel). 2015 Mar 16;5(1):61-83. doi: 10.3390/diagnostics5010061. PMID 26854143
- BACKGROUNDZangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S135-42. doi: 10.1007/s00259-004-1536-7. Epub 2004 May 5. PMID 15133636
- BACKGROUNDVogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, Jensen JD, Asmussen JT, Jylling AMB, Braad PE, Vach W, Ewertz M, Hildebrandt MG. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing 18F-FDG PET/CT with Conventional CT. J Nucl Med. 2023 Mar;64(3):355-361. doi: 10.2967/jnumed.121.263358. Epub 2022 Oct 7. PMID 36207136
- BACKGROUNDLoibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021 May 8;397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3. Epub 2021 Apr 1. PMID 33812473
- BACKGROUNDHadebe B, Harry L, Ebrahim T, Pillay V, Vorster M. The Role of PET/CT in Breast Cancer. Diagnostics (Basel). 2023 Feb 6;13(4):597. doi: 10.3390/diagnostics13040597.